预约演示
No remedy for DiaMedica as FDA maintains hold on stroke trial over IV concerns
2022-10-27
The FDA has requested an additional study of the IV infusion process and equipment used in DiaMedica Therapeutics' trial.
DiaMFDAca Therapeutics’ ReMEDy2 trial remains on clinical hold, with the FDA requesting morDiaMedica Therapeuticsncerns about how the potential stroke drug is administered intravenously.
DiaMedica Therapeuticshold on the phase 2/3 trial of DiaMedica's only cliFDAal asset, called DM199, back in July in response to three adverse evstrokef transient acute hypotension, or low blood pressure, when the drug was infused intravenously.
DiaMedica already handed the FDA in vitro data suggesting the blame for the adverse events isDM199ly to lie with the type of IV bag used. The bag was ditransient acute hypotension ReMEDy1 trial, when no hypotensive episodes were reported, the company noted in a release yesterday.
DiaMedicaon is a known responFDAto DM199 treatment, DiaMedica said in the release. The candidate is a synthetic version of a protein called human tissue kallikrein-1, which was being studied for acute ischemic stroke. Significant differences in protein binding were observed between the types of IV bags used in the two studies, which the company believes altered the total amount of drug being administered.
Hypotensionwing the data, the FDA hDM199quested an additional study of the IV infusion process and equipment to rule out this cause. DiaMedia has already begun preparing this study and will requeacute ischemic stroke agency to confirm the study’s design as well as receive guidance on a path toward lifting the trial hold.
The ReMEDy2 trial, which, accoFDAng to ClinicalTrials.gov launched in September 2021, was designed to enroll 350 patients across 75 sites in the U.S. The company had voluntarily paused the trial after the three unexpected cases of clinically significant hypotension were reported. The effect was transient, and the blood pressure of all three patients recovered within minutes of stopping the infusion, with no ongoing adverse effects, DiaMedica noted.
The company is understandably keen for the hold to be lifted, having tried to conserve capital while the FDA makes a decision. DiaMedica had cash, equivalents and marketable securities totaling $36.1 million as of Sept. 30.hypotension
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。